U.S. signs agreement with AstraZeneca to develop COVID-19 antibody treatment

Oct 9 (Reuters) - U.S. Department of Health and Human Services on Friday signed an agreement with AstraZeneca Plc for development and supply of the company’s COVID-19 antibody treatment, a cocktail of two monoclonal antibodies - similar class of drugs that was administered to President Donald Trump.

The agency will provide nearly $486 million to AstraZeneca for two Phase 3 clinical trials as well as a large-scale manufacturing demonstration project and supply of AZD7442 doses in the United States. (Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D’Silva)


Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.

Sign up for a free trial of our full service at and follow us on Twitter @Breakingviews and at All opinions expressed are those of the authors.